MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Combined catechol-O-methyl-transferase inhibition and intrajejunal Levodopa infusion: A real-life single-centre experience

    R.N. Taddei, V. Leta, A. Sauerbier, M. Parry, A. Podlewska, L. Hall, S. Tentis, P. Odin, W. Poewe, P. Dubois, D. van Warmelen, E.W. Lim, K.R. Chaudhuri (London, United Kingdom)

    Objective: To explore if catechol-O-methyl-transferase inhibition (COMT-I) can prolong the efficacy of daytime intrajejunal Levodopa infusion (IJLI) in Parkinson’s disease (PD) along with a reduction…
  • 2018 International Congress

    A novel mGlu4 PAM alleviates motor symptoms in primate models of PD and of LID

    D. Charvin, T. Di Paolo, E. Bezard, L. Gregoire, A. Takano, G. Duvey, E. Pioli, C. Halldin, R. Medori, F. Conquet (Plan-les-Ouates, Switzerland)

    Objective: Objective was to assess the therapeutic potential of our novel mGlu4 positive allosteric modulator (PAM), foliglurax, as an anti-parkinsonian treatment in gold-standard primate models.…
  • 2018 International Congress

    Efficacy of opicapone in Parkinson’s disease patients with ‘early’ motor fluctuations: NMSS analysis from the BIPARK-I double-blind experience

    A. Antonini, J. Ferreira, W. Poewe, O. Rascol, H. Gama, E. Arbe, J-F. Rocha, P. Soares-da-Silva (Padova, Italy)

    Objective: To evaluate the impact on non-motor symptoms in levodopa-treated Parkinson’s Disease (PD) patients with ‘early’ motor fluctuations. Background: Opicapone (OPC), a new once-daily COMT…
  • 2018 International Congress

    Epidemiological and clinical profile of Parkinson’s disease in Douala

    J. Doumbe, H. Bohongwe, Y. Mapoure, C. Kuate (Douala, Cameroon)

    Objective: The aim of our study was to determine the hospital prevalence and describe the epidemiological and clinical profile of Parkinson’s disease in Douala Background:…
  • 2018 International Congress

    Surface mechanised nano-formulation of naringenin as adenosine A2A receptor antagonist against in Neurological associated problem of Parkinson

    V. Kumar (Allahabad, India)

    Objective: In the current experimental study, we intended to develop Surface mechanized nano-formulation of naringenin (NG) as potent A(2A)AR antagonists against parkinson’s disease. Background: One…
  • 2018 International Congress

    What makes a successful Phase 2 study: An evaluation of Parkinson’s neuroprotective trial design over the last 5 years

    T. Dominey, S. Buff, G. Rafaloff, C. Carroll (Plymouth, United Kingdom)

    Objective: To evaluate variation in Phase 2 and 3 Parkinson’s disease (PD) neuroprotective trial designs and identify key trial design features in Phase 2 studies…
  • 2018 International Congress

    Dual task in the daily life of patients with Parkinson’s disease

    K. Mejia (Lima, Peru)

    Objective: Determine which of the types of motor or cognitive tasks interfere most severely in the dual task in the daily life of patients with…
  • 2018 International Congress

    Efficacy and security starting safinamide treatment with 100 mg/day in PD

    N. Foncea (Galdakao, Spain)

    Objective: Evaluating the efficacy and security starting safinamide treatment with 100 mg/day in PD Background: Dopaminergic treatment has been useful in PD. Other neurotransmission mechanisms…
  • 2018 International Congress

    Impact on the Quality of Life (CV) of people with Parkinson’s disease participating in community workshops of the public health system of Coquimbo, Chile

    S. Stange, D. Mansilla, Y. Diaz, Y. Córdoba (Coquimbo, Chile)

    Objective: To show the Impact in the CV of the People with Parkinson's Disease through the permanent assistance to the multidisciplinary community workshops of their…
  • 2018 International Congress

    Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic therapy

    A. Videnovic, S. Rutten, W. Croft, H. Erickson, J. Groves, C. Havemann, T. Herrington, S. Hendrix, K. Kieburtz, Y. vander Werf, O. vanden Heuvel (Boston, MA, USA)

    Objective: To evaluate the safety and effectiveness of Spectramax™ specialized bandwidth light therapy (LT) as adjunctive treatment in Parkinson’s disease (PD). Background: Previous studies have…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley